A multi-institutional study focused on how subtle challenges to women’s authority accumulate over time, leading to increased rates of burnout, discouraging women from staying in male-dominated careers.
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.
Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.
Excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease, according to research from the International Agency for Research on Cancer. The study was published in Cancer.
Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.
Artificial intelligence could enhance how tumor samples are analyzed in the lab—significantly improving how doctors determine the best treatment for cancer patients, a study by researchers at the Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center, and other collaborators suggests.
Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.
Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
